东亚药业(605177) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥314,792,722.32, a decrease of 4.70% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥12,696,106.90, down 58.98% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥11,151,688.98, a decline of 59.39% compared to the previous year[3]. - Basic earnings per share for Q3 2024 were ¥0.11, a decrease of 59.26% year-on-year[3]. - Net profit for the third quarter of 2024 was CNY 45,155,998.40, down 47.3% from CNY 85,562,429.83 in the same quarter of 2023[15]. - The total comprehensive income attributable to the parent company for Q3 2024 was ¥45,169,152.65, compared to ¥85,562,429.83 in Q3 2023[17]. - The company reported a total comprehensive income of ¥45,155,998.40 for Q3 2024, down from ¥85,562,429.83 in Q3 2023[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,516,801,373.43, an increase of 5.19% compared to the end of the previous year[3]. - The total assets increased to CNY 3,516,801,373.43, up from CNY 3,343,345,301.82, showing growth in the company's financial position[12]. - The total liabilities reached CNY 1,497,140,933.69, compared to CNY 1,328,072,150.07, indicating an increase in financial obligations[12]. - The equity attributable to shareholders increased slightly to CNY 2,019,573,593.99 from CNY 2,015,273,151.75, reflecting stable shareholder value[12]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥122,171,827.66[3]. - The net cash flow from operating activities for the first three quarters of 2024 was -¥122,171,827.66, worsening from -¥97,862,993.47 in the first three quarters of 2023[18]. - The net cash flow from financing activities for Q3 2024 was -¥18,212,659.25, a significant decline from ¥708,538,497.82 in Q3 2023[19]. - The company's cash and cash equivalents amount to ¥293,976,526.18, a decrease from ¥711,124,397.81 at the end of 2023[10]. - Cash and cash equivalents at the end of Q3 2024 decreased to ¥284,410,726.18 from ¥966,622,139.54 at the end of Q3 2023[19]. Expenses - The company reported a significant increase in management and R&D expenses, contributing to the decline in net profit[6]. - Total operating costs increased to CNY 914,079,555.24, up from CNY 906,324,880.93, reflecting a rise in operational expenses[13]. - Research and development expenses rose to CNY 67,140,483.98, compared to CNY 53,599,947.01 in the previous year, indicating a focus on innovation[15]. - The company reported a significant increase in management expenses to CNY 127,438,407.37 from CNY 96,396,943.30, which may affect profitability[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,147[8]. - The largest shareholder, Chi Zhengming, holds 47,116,769 shares, representing 41.06% of the total shares[8]. - The actual controllers of the company are Chi Zhengming and Chi Cheng, holding a combined voting power of 33.5295%[9]. Future Outlook - The company plans to focus on improving operational efficiency and managing costs to enhance profitability in the upcoming quarters[6].